Search results for: Health Policy and Regulation
Filter search results
25 Years of the Cost Effectiveness Acceptability Curve
30 December 2019
…health economic evaluations, and incorporated into health technology assessment methods guidelines in the UK and internationally. ISPOR President and OHE Research Fellow Professor Nancy Devlin and Professor Andrew Briggs of…
The Trump Administration’s US Drug Pricing Proposal – What will happen next?
12 June 2025
…prices are a result of the nature and design of the US healthcare system. This complexity is multi-factorial, with its mix of public and private providers, insurers and funders, and…
Cost-Effectiveness Thresholds and Expert Elicitation: a Bridge Too Far?
29 April 2021
…28 Apr. 2021]. Karlsberg Schaffer, S., Sussex, J., Devlin, N. and Walker, A., 2015. Local health care expenditure plans and their opportunity costs. Health Policy (Amsterdam, Netherlands), 119(9), pp.1237–1244. 10.1016/j.healthpol.2015.07.007. Karlsberg…
Around The World in HTAs: Türkiye – The bumpy road toward transformation
31 January 2024
…health workers, especially nurses and doctors. The uneven distribution of specialists exacerbates regional disparities in access to healthcare. The Turkish health system is highly consolidated under the Ministry of Health…
Does the New CBO Report Change Anything?
15 September 2021
…areas, no account for how science and therefore the cost and risk of R&D has changed, and no measure of the impact on the health of the population. From the…
What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
19 November 2024
…timing and topic, and its explicit relevance to this live and evolving policy question, we summarise the EEPRU paper’s analysis in this article and offer a short critique, outlining the…
Immunoglobulin sustainability in the United Kingdom
8 October 2026
…and future challenges to immunoglobulin (Ig) sustainability in the UK, assesses the implications for patients, services and cost, and sets out prioritised policy responses. The findings draw on a targeted…
OHE’s AMR consultation response
21 November 2023
…across 17 criteria that cover aspects of clinical effectiveness, global and national needs, pharmacological benefits, and health system benefits. Each criterion is associated with scores and a weight (Figure 1)…
The value of fast diagnostics in time-critical infections
20 April 2026
…Japan, the United Kingdom, and the United States) and incorporates expert‑validated clinical inputs, country‑specific cost data, and conservative assumptions. The findings show meaningful health gains, substantial cost savings, and consistent…